Merck & Company Inc (MRK)vsScinai Immunotherapeutics Ltd (SCNI)
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
SCNI
Scinai Immunotherapeutics Ltd
$0.74
+3.67%
HEALTHCARE · Cap: $2.06M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 4958786% more annual revenue ($65.01B vs $1.31M). MRK leads profitability with a 28.1% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
SCNI
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Margin of Safety
+52.8%
Fair Value
$1.59
Current Price
$0.74
$0.85 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Reasonable price relative to book value
Revenue surging 30.6% year-over-year
Earnings expanding 87.2% YoY
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
ROE of -91.9% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : SCNI
The strongest argument for SCNI centers on Price/Book, Revenue Growth, EPS Growth. Revenue growth of 30.6% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : SCNI
The primary concerns for SCNI are Market Cap, Profit Margin, Piotroski F-Score.
Key Dynamics to Monitor
MRK profiles as a value stock while SCNI is a hypergrowth play — different risk/reward profiles.
SCNI carries more volatility with a beta of 1.99 — expect wider price swings.
SCNI is growing revenue faster at 30.6% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 48/100), backed by strong 28.1% margins. SCNI offers better value entry with a 52.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Scinai Immunotherapeutics Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Scinai Immunotherapeutics Ltd is a cutting-edge biotechnology company specializing in the development of innovative immunotherapy solutions aimed at treating cancer and autoimmune disorders. Utilizing its proprietary immune modulation platform, Scinai is advancing a robust clinical pipeline that focuses on delivering transformative therapies to improve patient outcomes. With a highly experienced leadership team and a commitment to rigorous research, the company is well-positioned to capitalize on the growing demand for advanced immunotherapeutics in the global healthcare landscape. Strategic partnerships further enhance Scinai's potential for significant growth, establishing it as a key player in the biopharmaceutical sector.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?